The study demonstrated a favourable safety profile for DT-9081.

Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity -- Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome ...

Kainova reports positive results from phase I EPRAD study of DT-9081, an oral EP4 receptor antagonist, in advanced solid tumours: Montreal, Canada Thursday, March 12, 2026, 17:00 ...

Chief Executive Officer Sean A MacDonald added: “The successful completion of this Phase I study represents an important step for Kainova Therapeutics, highlighting the strength of our innovative ...

OKN4395 is the first Owkin development program to leverage K1.0, Owkin’s AI-powered Operating System, from asset selection to clinical development optimization This asset is a highly selective triple ...

Familial adenomatous polyposis is an inherited condition that significantly increases the risk for colon cancer. The Food and Drug Administration (FDA) has granted Orphan Drug designation to TPST-1495 ...

Researchers from Kanaph Therapeutics Inc. and Korea Research Institute of Chemical Technology have disclosed prostanoid EP2 and/or EP4 receptor subtype dual antagonists reported to be useful for the ...

Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activityReinforce EP4 receptor antagonism as a validated, high-value strategy to overcome immun ...